A Human Fab-Based Immunoconjugate Specific for the LMP1 Extracellular Domain Inhibits Nasopharyngeal Carcinoma Growth In Vitro and In Vivo
Authors:
- Dawei ZhangDZDawei Zhang
- Yuan MaoYMYuan Mao
- Jin ZhuJZJin Zhu
- Hao MingHMHao Ming
- Juan WenJWJuan Wen
- Jun MaJMJun Ma
- Qing CaoQCQing Cao
- Hong LinHLHong Lin
- Qi TangQTQi Tang
- Jie LiangJLJie Liang
- Zhenqing FengZFZhenqing Feng
Open Access
- 1 March 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 11 (3) , 594-603
Abstract
Nasopharyngeal carcinoma (NPC) is a major cause of cancer-related death in Southeast Asia and China. Metastasis and relapse are the primary cause of morbidity and mortality in NPC. Recent evidence suggests that the Epstein–Barr virus latent membrane protein 1 (LMP1) is exclusively expressed in most NPC and is a potential target for biotherapy. In this study, we successfully prepared a novel human antibody Fab (HLEAFab) against LMP1 extracellular domain, which was subsequently conjugated with mitomycin C (MMC), thus forming an immunoconjugate (HLEAFab-MMC). The effects of HLEAFab-MMC on proliferation and apoptosis in NPC cell lines HNE2/LMP1 and the inhibition rate of growth of NPC xenografts in nude mice were examined. The inhibition rate of HNE2/LMP1 cell proliferation was the highest for HLEAFab-MMC (76%) compared with MMC (31%) and HLEAFab (22%) at a concentration of 200 nmol/L and showed dose-dependent fashion. The apoptosis rate of HNE2/LMP1 cell lines was 13.88% in HLEAFab-MMC group, 3.04% in MMC group, 2.78% in HLEAFab group, and 2.10% in negative control group at the same concentration, respectively. In vivo, the inhibition rate of growth of NPC xenografts in nude mice was 55.1% in HLEAFab-MMC group, 26.5% in MMC group, and 5.64% in HLEAFab group. In summary, our findings show that HLEAFab-MMC is a unique immunoconjugate with the potential as a novel therapeutic agent in the treatment of LMP1-expressing NPC. Mol Cancer Ther; 11(3); 594–603. ©2011 AACR.Keywords
This publication has 31 references indexed in Scilit:
- Recurrent Nasopharyngeal CarcinomaAmerican Journal of Clinical Oncology, 2010
- Epstein‐Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemiaCancer, 2010
- Role of The Epstein–Barr Virus-Encoded Latent Membrane Protein-1, LMP1, in The Pathogenesis of Nasopharyngeal CarcinomaFuture Oncology, 2009
- Isolation of Osteosarcoma‐Associated Human Antibodies from a Combinatorial Fab Phage Display LibraryBioMed Research International, 2009
- LGI1 and LGI4 bind to ADAM22, ADAM23 and ADAM11International Journal of Biological Sciences, 2008
- Targeting the active site of the placental isozyme of alkaline phosphatase by phage-displayed scFv antibodies selected by a specific uncompetitive inhibitorBMC Biotechnology, 2005
- Epstein–Barr virus encoded latent membrane protein 1 modulates nuclear translocation of telomerase reverse transcriptase protein by activating nuclear factor-κB p65 in human nasopharyngeal carcinoma cellsThe International Journal of Biochemistry & Cell Biology, 2005
- Construction of Human Naïve Fab Library and Characterization of Anti-Met Fab Fragment Generated From the LibraryMolecular Biotechnology, 2005
- Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomasEuropean Journal of Cancer, 1995
- Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective studyNature, 1978